Ayala Pharmaceuticals, Inc.

ADXSCIK 0001100397 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 26, 2024. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone -0.0010

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

Recent 8-K announcements

Per-item disclosure feed. Item 2.02 is the earnings release.

Apr 19, 2024no items parsed Apr 3, 2024no items parsed Mar 29, 2024no items parsed Mar 5, 2024no items parsed Feb 23, 2024no items parsed

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Ayala Pharmaceuticals, Inc.

Name	Roles	Filings
Israel Biotech Fund I, L.P.	Director10% Owner	6
Israel Biotech Fund II, L.P.	Director10% Owner	6
I.b.f. Management Ltd.	Director10% Owner	5
Israel Biotech Fund Gp Partners II, L.P.	Director10% Owner	5
Israel Biotech Fund Gp Partners, L.P.	Director10% Owner	5

Showing 1-5 of 10

Per pagePage 1 of 2Next

All filings

11 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Jan 23, 2023	Sidransky David Director	AGrant	46	-	-

Showing 11-11 of 11

Per pagePrevPage 3 of 3

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value